Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
STOCKS
Goodbye CytRx, Your Game Is Over
By Adam Feuerstein
Jun 5, 2017 11:55 PM EDT
PRESS RELEASES
CytRx Highlights Use Of Aldoxorubicin In Phase 2 Clinical Trials Yielding Positive Interim Data On Survival Rates In Metastatic Pancreatic Cancer Patients
By Business Wire
Jan 15, 2021 8:00 AM EST
PRESS RELEASES
CytRx Issues Statement Regarding U.S. Regulatory Review Of Arimoclomol For Niemann-Pick Disease Type C
By Business Wire
Dec 31, 2020 2:00 PM EST
PRESS RELEASES
CytRx Comments On Proposed Combination Of ImmunityBio And NantKwest
By Business Wire
Dec 22, 2020 8:00 AM EST
PRESS RELEASES
CytRx Comments On Quarterly Results And Recent Strategic Progress
By Business Wire
Nov 16, 2020 8:00 AM EST
PRESS RELEASES
CytRx Highlights Orphazyme's Submission Of European Marketing Authorisation For Arimoclomol To Treat Niemann-Pick Disease Type C
By Business Wire
Nov 11, 2020 8:00 AM EST
PRESS RELEASES
CytRx Highlights Orphazyme's Acceleration Of Pre-Launch Activities For Arimoclomol
By Business Wire
Oct 27, 2020 8:00 AM EDT
PRESS RELEASES
CytRx Highlights Use Of Licensed Drug Aldoxorubicin In Treatment Of Former Senate Majority Leader Harry Reid's Pancreatic Cancer
By Business Wire
Oct 7, 2020 8:00 AM EDT
PRESS RELEASES
CytRx Issues Statement Regarding Orphazyme's Global Offering
By Business Wire
Sep 30, 2020 8:00 AM EDT
PRESS RELEASES
CytRx Highlights Orphazyme's Receipt Of FDA Acceptance And Priority Review Of Its New Drug Application For Arimoclomol For Niemann-Pick Disease Type C
By Business Wire
Sep 17, 2020 8:00 AM EDT
PRESS RELEASES
CytRx Announces Voting Results From 2020 Annual Meeting And Issues New Investor Presentation
By Business Wire
Sep 3, 2020 4:00 PM EDT
PRESS RELEASES
CytRx Announces Initiatives To Strengthen Corporate Governance And Support Strategic Priorities
By Business Wire
Aug 24, 2020 8:00 AM EDT
PRESS RELEASES
CytRx Corporation Highlights Orphazyme's Completion Of Rolling Submission Of Its New Drug Application With The U.S. FDA For Arimoclomol In Niemann-Pick Disease Type-C
By PR Newswire
Jul 21, 2020 9:00 AM EDT
PRESS RELEASES
CytRx Corporation Highlights Orphazyme's Announcement Of Its Phase 2 Study Results With Arimoclomol In Gaucher Disease
By PR Newswire
Jun 29, 2020 9:00 AM EDT
PRESS RELEASES
CytRx Corporation Highlights Orphazyme's Rolling Submission Of Its New Drug Application With The U.S. FDA For Arimoclomol In Niemann-Pick Disease Type-C
By PR Newswire
Jun 1, 2020 9:00 AM EDT
PRESS RELEASES
CytRx Corporation Highlights Latest Positive Event From Its Licensed Drug Aldoxorubicin
By PR Newswire
May 21, 2020 9:00 AM EDT
PRESS RELEASES
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided By Orphazyme A/S In Niemann-Pick Disease
By PR Newswire
Apr 29, 2020 9:00 AM EDT
PRESS RELEASES
CytRx Corporation Provides Update On Management Change
By PR Newswire
Mar 10, 2020 9:00 AM EDT
PRESS RELEASES
CytRx Corporation Clarifies Certain Prior Disclosures Regarding Its Relationship With Orphazyme A/S
By PR Newswire
Feb 28, 2020 9:00 AM EST
PRESS RELEASES
CytRx Corporation Highlights Recently Published Data Of Its Licensee Orphazyme A/S Phase 2 Trial Of Arimoclomol In The Treatment Of Sporadic Inclusion Body Myositis (sIBM)
By PR Newswire
Feb 11, 2020 9:00 AM EST
PRESS RELEASES
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided By Licensee Orphazyme A/S
By PR Newswire
Feb 4, 2020 9:00 AM EST
PRESS RELEASES
CytRx Corporation Highlights Significant Positive Events From Its Licensed Drug Aldoxorubicin
By PR Newswire
Jan 29, 2020 9:00 AM EST
STOCKS
Goodbye CytRx, Your Game Is Over
By Adam Feuerstein
Jun 5, 2017 11:55 PM EDT
STOCKS
For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1
By Adam Feuerstein
Apr 11, 2017 1:46 PM EDT
INVESTING
The 'Gnarly 9' biotechs will test FDA mettle
By Adam Feuerstein
Mar 8, 2017 12:40 PM EST
